Cardiovascular disease and risk factors among psoriasis patients in two US Healthcare databases, 2001-2002

被引:131
作者
Kimball, A. B. [2 ]
Robinson, D., Jr. [1 ]
Wu, Y. [1 ]
Guzzo, C. [3 ]
Yeilding, N. [3 ]
Paramore, C. [4 ]
Fraeman, K. [4 ]
Bala, M. [1 ]
机构
[1] Johnson & Johnson Pharmaceut Serv, Malvern, PA 19355 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Centocor Inc, Centocor Res & Dev, Malvern, PA 19355 USA
[4] UBC, Bethesda, MD USA
关键词
psoriasis; dermatology; comorbidity; treatment; epidemiology; autoimmune;
D O I
10.1159/000121333
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Cardiovascular diseases or risk factors ( CVDR) seem to be more common in psoriasis patients than in the general population. Objective: We assessed the relationship of psoriasis with CVDR by analysis of healthcare claims data using a cross-sectional, prevalence-based study design. Patients and Methods: The IMS Health and MarketScan (R) claims databases were used to identify adults with psoriasis diagnostic codes. Non-psoriasis controls were matched 3: 1 based on age, gender, census region and previous medical insurance coverage. Odds ratios evaluated the relative prevalence of CVDR, and Mantel-Haenszel confidence intervals were estimated. Results: CVDR prevalence was generally higher in psoriasis patients than controls in both datasets. Odds ratios for atherosclerosis, congestive heart failure, type 2 diabetes, and peripheral vascular disease were >= 1.20 for psoriasis patients. Elevated disease severity was associated with a higher rate of CVDR, but varied somewhat by dataset and condition. Conclusions: Elevated CVDR rates were found in psoriasis patients compared with controls. This pattern merits further examination. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:27 / 37
页数:11
相关论文
共 33 条
[1]   Disease and disadvantage in the United States and in England [J].
Banks, J ;
Marmot, M ;
Oldfield, Z ;
Smith, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17) :2037-2045
[2]   The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US [J].
Crown, WH ;
Bresnahan, BW ;
Orsini, LS ;
Kennedy, S ;
Leonardi, C .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) :1929-1936
[3]  
ENA P, 1985, ACTA CARDIOL, V40, P199
[4]   Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan [J].
Feldman, SR ;
Evans, C ;
Russell, MW .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (01) :37-42
[5]   Prevalence and treatment of psoriasis in the United Kingdom - A population-based study [J].
Gelfand, JM ;
Weinstein, R ;
Porter, SB ;
Neimann, AL ;
Berlin, JA ;
Margolis, D .
ARCHIVES OF DERMATOLOGY, 2005, 141 (12) :1537-1541
[6]   Risk of myocardial infarction in patients with psoriasis [J].
Gelfand, Joel M. ;
Neimann, Andrea L. ;
Shin, Daniel B. ;
Wang, Xingmei ;
Margolis, David J. ;
Troxel, Andrea B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (14) :1735-1741
[7]   Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease [J].
Ghoreschi, K ;
Thomas, P ;
Breit, S ;
Dugas, M ;
Mailhammer, R ;
van Eden, W ;
van der Zee, R ;
Biedermann, T ;
Prinz, J ;
Mack, M ;
Mrowietz, U ;
Christophers, E ;
Schlöndorff, D ;
Plewig, G ;
Sander, CA ;
Röcken, M .
NATURE MEDICINE, 2003, 9 (01) :40-46
[8]  
Han CL, 2006, J RHEUMATOL, V33, P2167
[9]   DISEASE CONCOMITANCE IN PSORIASIS [J].
HENSELER, T ;
CHRISTOPHERS, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 32 (06) :982-986
[10]   The psychosocial burden of psoriasis [J].
Kimball, AB ;
Jacobson, C ;
Weiss, S ;
Vreeland, MG ;
Wu, Y .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (06) :383-392